MS Active Source

Treatment

• Introduction
• Introduction to MS
• MS treatments
  • Intro to MS treatments
  • Interferons
  • Avonex
  • Betaferon
  • Rebif
  • Glatiramer acetate
  • Copaxone
  • Natalizumab
  • Tysabri
  • Treatment of relapses
  • Risk-sharing scheme
  • Progressive MS
• Positive approach
• Newly diagnosed?
• Relative with MS
• Links
• Principles of treatment

Betaferon (Interferon Beta-1b) ( refT10 )

Betaferon (interferon beta-1b), known in the USA as Betaseron, may be given to people with RRMS who have had two or more relapses during the last 2 years. It may also be given to people with secondary progressive MS with active disease (i.e. relapses) and to people with a single demyelinating event with an active inflammatory process if it is severe enough to warrant treatment with intravenous corticosteroids.

Betaferon is a suitable treatment for people with RRMS and two or more relapses within the last two years and patients with SPMS with active disease, evidenced by relapses.

Betaferon is given as a subcutaneous injection (under the skin), at a dose of 250 µg (micrograms), every other day. It is not known for how long patients should be treated. After 2 years of treatment, all patients should be assessed by their neurologist and decisions about longer-term treatment made on an individual basis.

Licensed in 1995, Betaferon is marketed by Bayer Schering Pharma AG.

Use of this product will be determind by your neurologist according to guidance layed out in the risk-sharing scheme. More information can be found by going to www.mstrust.org.uk

More detailed prescribing information on Betaferon can be found by going to www.medicines.org.uk. typing Betaferon into the search box and pressing Go. This should take you to the patient information leaflet that is packaged with the drug.

Quick Links

• Treatment rights
• Your questions
• Glossary
• Making the most of treatment
• Newly diagnosed

Supported by